Antibody-Oligonucleotide Conjugate Shows Promise in Myotonic Dystrophy Type 1

(MedPage Today) — Investigational delpacibart etedesiran (del-desiran) showed promise in the Phase I/II MARINA trial in myotonic dystrophy type 1 (DM1), a rare progressive disorder caused by a toxic gain-of-function mutation in the DM1 protein…